For small, early stage biotech
companies, 2012 could be the year of living creatively.
Although public biotechs raised
more funds last year than ever before, the vast majority of the money was debt
financing by established companies with marketed products. Thus while the
overall numbers look good and are likely to continue to do so, precommercial
companies will have to get creative with their financings.